Clinical trials: Active Population
Neurofibromatosis 1, Cutaneous Neurofibroma
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a study doctor for approximately 56 days.
- Trial name
- NCT04435665
- Testing
- NFX-179 Gel, Vehicle Gel
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- NFlection Therapeutics, Inc.
Acute Gastritis, Chronic Gastritis
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.
This is a multicenter, active-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 4-week treatment with Stillen tab. in patients with acute or chronic gastritis.
- Trial name
- NCT01817556
- Testing
- Stillen Tab., Mucosta Tab.
- Where
- South Korea
- Volunteers
- 258 people
- Sponsor
- Dong-A ST Co., Ltd.
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Anaemia
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
- Trial name
- NCT02876835
- Testing
- Daprodustat, Darbepoetin alfa, Iron Therapy
- Where
- 574 sites in United States, Argentina and 37 more
- Volunteers
- 3,872 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: To evaluate the other safety aspects of sarilumab administered as monotherapy.
- Trial name
- SARIL-RA-ONE (NCT02121210)
- Testing
- sarilumab SAR153191 (REGN88)
- Where
- 28 sites in United States, Chile and 5 more
- Volunteers
- 132 people
- Sponsor
- Sanofi
Crohn's Disease
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China.
- Trial name
- NCT05837897
- Testing
- Vedolizumab IV
- Where
- 43 sites in China
- Volunteers
- 408 people
- Sponsor
- Takeda
Diabetic Nephropathies
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting…
- Trial name
- NCT03165240
- Testing
- BI 690517, Eplerenone
- Where
- 40 sites in Denmark, France and 8 more
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Seasonal Allergic Rhinitis
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
The purpose of this study is to compare once daily treatment with Rhinocort against placebo and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
- Trial name
- NCT00641680
- Testing
- Budesonide, Fluticasone propionate
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Oral Contraceptive
Comparative Trial in Hormone Withdrawal Associated Symptoms
This clinical research study will examine whether an oral contraceptive pill taken with a monthly hormone-free interval of 4 days reduces hormone withdrawal associated symptoms compared to an oral contraceptive pill taken with a…
- Trial name
- NCT01076582
- Testing
- EE20/DRSP (YAZ, BAY86-5300), Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
- Where
- 44 sites in Argentina, Chile and 12 more
- Volunteers
- 592 people
- Sponsor
- Bayer
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- NCT05018013
- Testing
- Ammoxetine hydrochloride enteric-coated tablets, Duloxetine hydrochloride enteric-coated capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Covid19
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
This is a 2-Stage, Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03…
- Trial name
- NCT05007951
- Testing
- GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units
- Where
- 38 sites in New Zealand, Philippines and 4 more
- Volunteers
- 4,036 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Parkinson's Disease
Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® PD01A vaccinations in patients with Parkinson's disease.
- Trial name
- AFF008A (NCT02216188)
- Testing
- AFFITOPE® PD01A, Control
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Affiris AG
Crohn Disease
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on…
- Trial name
- NCT02513459
- Testing
- Risankizumab 600 mg IV, Risankizumab 180 mg SC
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- AbbVie
Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
- Trial name
- PEAPOD (NCT04804553)
- Testing
- Apremilast
- Where
- 44 sites in Belgium, France and 12 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Arthritis, Rheumatoid
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered…
- Trial name
- SIRROUND-H (NCT02019472)
- Testing
- adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 559 people
- Sponsor
- Janssen Research & Development, LLC
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Cancer Pain
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.
- Trial name
- SWITCH (NCT02660229)
- Testing
- Oxycodone Hydrochloride, Morphine Sulphate
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Mundipharma Korea Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.